Search

Displaying results 4781 - 4790 of 7018 in total
  1. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy. … Ginsenosides are a class of steroid glycosides, and triterpene saponins, found exclusively in the plant genus Panax (ginseng).

    Synonyms: Panaxoside A, Ginsenoside A2
  2. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

  3. Drug

    Elafin

    go.drugbank.com/drugs/DB05161
    Investigational

    Elafin’s ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or … The excellent tolerability of Elafin in human subjects was demonstrated in a Phase I clinical single dose escalating study.

  4. Drug

    Cyamemazine

    go.drugbank.com/drugs/DB09000
    Experimental

    Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class used primarily in the treatment of schizophrenia and psychosis-associated anxiety. … Cyamemazine actually behaves like an atypical antipsychotic, due to its potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).

  5. Drug

    Fluorodopa (18F)

    go.drugbank.com/drugs/DB13848
    ApprovedInvestigational

    Fluorodopa F 18 is a fluorinated analog of [levodopa] used as a diagnostic agent for positron emission tomography (PET) in the evaluation of Parkinsonian syndromes.

  6. Drug

    ATG-101

    go.drugbank.com/drugs/DB17162
    Investigational

    , while delivering enhanced anti-tumor activity, with an improved safety profile. … ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors

  7. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. … Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.

  8. Drug

    Tolazoline

    go.drugbank.com/drugs/DB00797
    ApprovedVet approvedWithdrawn

    A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. … It is used in treatment of persistent pulmonary hypertension of the newborn.

  9. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. … It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

  10. Drug

    Covax-19™

    go.drugbank.com/drugs/DB15846
    Investigational

    Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073).